Epizyme (EPZM) Shares Down 0%

Epizyme (NASDAQ:EPZM)’s share price traded down 0% during mid-day trading on Friday . The stock traded as low as $14.70 and last traded at $14.85. 513,598 shares traded hands during trading, an increase of 14% from the average session volume of 449,521 shares. The stock had previously closed at $14.85.

Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Thursday, March 15th. BidaskClub upgraded Epizyme from a “hold” rating to a “buy” rating in a research report on Thursday, March 15th. SunTrust Banks reiterated a “buy” rating and issued a $27.00 price objective on shares of Epizyme in a report on Wednesday, March 14th. Leerink Swann increased their price objective on Epizyme from $22.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, March 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $25.00 price objective (down previously from $26.00) on shares of Epizyme in a report on Wednesday, March 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the stock. Epizyme currently has a consensus rating of “Buy” and an average target price of $23.50.

How to Become a New Pot Stock Millionaire

Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.05. The firm’s revenue for the quarter was down 100.0% compared to the same quarter last year. analysts forecast that Epizyme will post -2.37 EPS for the current fiscal year.

In other news, COO Matthew Ros sold 72,264 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $16.63, for a total value of $1,201,750.32. Following the completion of the transaction, the chief operating officer now owns 74,867 shares in the company, valued at approximately $1,245,038.21. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 25.20% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas purchased a new position in shares of Epizyme in the 4th quarter valued at approximately $202,000. Fox Run Management L.L.C. lifted its stake in shares of Epizyme by 64.7% in the 4th quarter. Fox Run Management L.L.C. now owns 19,275 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 7,575 shares during the period. Bailard Inc. purchased a new position in shares of Epizyme in the 4th quarter valued at approximately $251,000. MetLife Investment Advisors LLC purchased a new position in shares of Epizyme in the 4th quarter valued at approximately $263,000. Finally, Virtus Fund Advisers LLC purchased a new position in shares of Epizyme in the 4th quarter valued at approximately $346,000. Institutional investors own 85.88% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3340855/epizyme-epzm-shares-down-0.html.

Epizyme Company Profile

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

-$0.29 Earnings Per Share Expected for Adverum Biotechnologies  This Quarter
-$0.29 Earnings Per Share Expected for Adverum Biotechnologies This Quarter
Rockwell Collins  & Spirit AeroSystems  Head to Head Analysis
Rockwell Collins & Spirit AeroSystems Head to Head Analysis
Analyzing AZZ  and LSI Industries
Analyzing AZZ and LSI Industries
Gold Fields  vs. The Competition Head-To-Head Survey
Gold Fields vs. The Competition Head-To-Head Survey
bitSilver  Achieves Market Capitalization of $452,865.00
bitSilver Achieves Market Capitalization of $452,865.00
TomoChain  Trading 56% Higher  Over Last 7 Days
TomoChain Trading 56% Higher Over Last 7 Days


© 2006-2018 Ticker Report. Google+.